ML28485: Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform, Nodular and Superficial) of High Risk and/or Locally Advanced Basal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 May 2019
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.